We are live on ! Find out more
ALXO icon

ALX Oncology

86 hedge funds and large institutions have $68.5M invested in ALX Oncology in 2024 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 31 increasing their positions, 20 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

124% more call options, than puts

Call options by funds: $427K | Put options by funds: $191K

55% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 20

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

5% less funds holding

Funds holding: 91 → 86 (-5)

8.44% less ownership

Funds ownership: 86.23% → 77.8% (-8.4%)

38% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 26

41% less capital inflows, than outflows

Capital inflows: $12.2M | Capital outflows: $20.9M

Holders
86
Holders Change
-5
Holders Change %
-5.49%
% of All Funds
1.13%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
16
Increased
31
Reduced
20
Closed
26
Calls
$427​K
Puts
$191​K
Net Calls
+$236​K
Net Calls Change
-⁠$66​K

ALXO Hedge Fund Activity: Q4 2024 in Review

86 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q4 2024, worth a combined $68.5M — down 17% from $82.7M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of ALXO and 16 opened new positions — a net loss of 10 holders — while 20 trimmed existing stakes and 31 added.

The largest buyer was Morgan Stanley, adding an estimated $3.35M. The largest seller was Vivo Capital, exiting entirely with an estimated $7.34M sold.

  • 86 institutional investors held ALX Oncology (ALXO) as of Q4 2024, down from 91 in Q3 2024.
  • Funds reported $68.5M of ALX Oncology stock for Q4 2024, down 17% quarter-over-quarter.
  • 16 funds opened new ALX Oncology positions in Q4 2024 and 26 closed out, a net change of -10 holders.
  • The largest ALX Oncology buyer in Q4 2024 was Morgan Stanley, an estimated $3.35M added.
  • The largest ALX Oncology seller in Q4 2024 was Vivo Capital, an estimated $7.34M sold.

Based on aggregated 13F filings for Q4 2024.